[an error occurred while processing this directive]

Journal of Chinese Integrative Medicine ›› 2005, Vol. 3 ›› Issue (5): 366-369.doi: 10.3736/jcim20050509

• Original Clinical Research • Previous Articles     Next Articles

Clinical observation on treatment of IgA nephropathy with Huobahuagen Tablets and irbesartan

Xiao-dong Guan1,Yu-fang Wu2,Wen Zhao1   

  1. 1. Department of Nephrology, Donghua Hospital, Sun Yat-sen University, Dongguan, Guangdong Province 523010, China
    2. Clinical Laboratory, Donghua Hospital, Sun Yat-sen University, Dongguan, Guangdong Province 523010, China
  • Received:2005-02-28 Online:2005-09-20 Published:2005-09-20
  • Contact: Xiao-dong Guan E-mail:333@163.com

RichHTML

1

PDF (PC)

96

Like

Objective

To observe the effects of Huobahuagen Tablets combined with irbesartan on the risk factors of IgA nephropathy.

Methods

Sixty-two patients diagnosed as IgA nephropathy were randomly divided into control group and treatment group. Thirty patients in the control group were treated with Huobahuagen Tablets (5 tablets po t.i.d.), and 32 patients in the treatment group were treated with irbesartan (150 to 300 mg po q.d.), besides the same treatment as the control group. After 3 months of treatment, the levels of blood pressure (BP), 24 h urine protein (Upr), urinary red blood cells (URBC), blood triglycerides (TG), total cholesterol (TC), albumin (Alb), alanine transaminase (ALT), white blood cells (WBC) and serum creatinine (Scr) were observed.

Results

After treatment, the levels of Upr, URBC and Scr in both groups were decreased, as compared with those before treatment (P<0.05 or P<0.01), and the levels of BP, Upr, URBC and Scr in the treatment group were lower than those in the control group (P<0.01). The levels of Alb in both groups were increased, as compared with those before treatment (P<0.05 or P<0.01), and the level of Alb in the treatment group was higher than that in the control group (P<0.05).

Conclusion

Huobahuagen Tablets, when used together with irbesartan, may improve the renal function of the patients with IgA nephropathy and slow the deterioration of the disease by reducing BP, Upr, URBC and Scr.

Key words: Huobahuagen Tablets, Irbesartan, Glomerulonephritis, IgA, Risk factors

CLC Number: 

  • R692.31

Tab 1

Changes of blood pressure in 2 groups （$\bar{x}$±s, mm Hg）"

Group n Systolic pressure Diastolic pressure
Control group
Before treatment 30 150.0±22.6 96.8±12.2
After treatment 30 148.6±21.8 96.4±12.6
Treatment group
Before treatment 32 152.0±22.8 98.5±11.6
After treatment 32 128.8±13.4**△△ 84.7±7.9**△△

Tab 2

Changes of laboratory indexes in 2 groups ($\bar{x}$±s )"

Group n Upr
(g/24 h)		 URBC
(cells/HP)		 Scr
(μmol/L)		 Alb
(g/L)		 TG
(mmol/L)		 TC
(mmol/L)		 ALT
(U/L)		 WBC
(109/L)
Control group
Before treatment 30 2.24±1.32 37.5±17.5 212.8±60.4 31.6±5.8 2.59±1.35 6.98±2.74 37.92±4.56 6.32±1.62
After treatment 30 0.98±0.42** 16.5±9.5** 182.4±36.2* 35.2±6.8* 2.52±1.27 6.86±2.65 39.86±9.26 5.52±1.48
Treatment group
Before treatment 32 2.26±1.27 38.5±16.5 216.4±56.2 31.4±5.6 2.65±1.32 6.63±2.65 37.10±4.62 6.20±1.60
After treatment 32 0.46±0.22**△△ 9.5±6.5**△△ 128.6±36.4**△△ 38.8±7.3**△ 2.58±1.24 6.23±2.83 40.13±9.31 5.46±1.52
[1] 叶任高 . IgA肾病的治疗近况[J]. 中国中西医结合肾病杂志, 2004,5(2):74
doi: 10.3969/j.issn.1009-587X.2004.02.004
[2] 侯凡凡, 梁敏 . 肾实质性高血压的合理治疗[J]. 中国中西医结合肾病杂志, 2003,4(6):311-313
doi: 10.3969/j.issn.1008-1070.2002.12.001
[3] 戎殳, 胡伟新, 刘志红 , 等. 系膜增生性肾小球肾炎的新疗法—雷公藤多甙新治疗方案的疗效观察[J]. 肾脏病与透析肾移植杂志, 1998,7(5):409-414
[4] 王海燕, 王梅 . 慢性肾脏病及透析的临床实践指南(第1版)[M]. 北京: 人民卫生出版社, 2003,( 第1版):192
[5] 章友康 . 肾病综合征[A]. 见:叶任高. 内科学[M]. 第5版. 北京: 人民卫生出版社, 2000. 532-538
[6] Shihab FS, Bennett WM, Tanner AM , et al. Angiotensin Ⅱ blockade decreases TGF-beta 1 and matrix proteins in cyclosporine nephropathy[J]. Kidney Int, 1997,52(3):660-673
doi: 10.1038/ki.1997.380 pmid: 9291185
[7] Wolf G, Ziyadeh FN . Renal tubular hypertrophy induced by angiotensin Ⅱ[J]. Semin Nephrol, 1997,17(5):448-454
doi: 10.1111/j.1525-139X.1997.tb00519.x pmid: 9316213
[8] Ruiz-Ortega M, Egido J . Angiotensin Ⅱ modulates cell growth-related events and synjournal of matrix proteins in renal interstitial fibroblasts[J]. Kidney Int, 1997,52(6):1497-1510
doi: 10.1038/ki.1997.480
[9] 朱吉莉, 贾汝汉, 王学玉 , 等. 厄贝沙坦对肾硬化大鼠肾小管间质中MMP-9/TIMP-1表达的影响[J]. 基础医学与临床, 2002,22(6):554-558
doi: 10.3969/j.issn.1001-6325.2002.06.017
[10] 黄昌亚, 余秉治, 熊飞 . 火把花根片联合苯那普利治疗IgA肾病的临床观察[J]. 湖北中医杂志, 2003,25(7):17
[1] Morufu Eyitayo Balogun, Elizabeth Enohnyaket Besong, Jacinta Nkechi Obimma, Ogochukwu Sophia Mbamalu, Fankou Serges Athanase Djobissie. Protective roles of Vigna subterranea (Bambara nut) in rats with aspirin-induced gastric mucosal injury. Journal of Integrative Medicine, 2018, 16(5): 342-349.
[2] Yi Chen, De-yu Fu, Yu Chen, Yan-ming He, Xiao-dong Fu, Yan-qiu Xu, Yi Liu, Xiao-tao Feng, Teng Zhang, Wen-jian Wang. Effects of Chinese herbal medicine Yiqi Huaju Formula on hypertensive patients with metabolic syndrome: A randomized, placebo-controlled trial. Journal of Chinese Integrative Medicine, 2013, 11(3): 184-194.
[3] Yin Fan Arthur, LixingLao, Rui-xin Zhang, An-nan Zhou, Brian M. Breman. Preclinical safety evaluation of the aqueous acetone extract of Chinese herbal formula Modified Huo Luo Xiao Ling Dan. Journal of Chinese Integrative Medicine, 2010, 8(5): 438-447.
[4] Jia Guo, Zong-wen Huang, Jing-yun Fan, Yan chen, Fu-qian He. Risk factor analysis of severe acute pancreatitis complicated by pancreatic encephalopathy. Journal of Chinese Integrative Medicine, 2008, 6(4): 352-354.
[5] Kai-wen Hu, Fen Wang, Yang Cao, Xiu-lan He, Ming-huan Zuo, Wen-qiang Chen. Risk factors of traditional Chinese medical syndromes in moderate and advanced lung cancer patients with concurrent fungal pneumonia. Journal of Chinese Integrative Medicine, 2004, 2(5): 337-339.
[6] Xing-gang Dong, Yi-ping Chen, Zeng-mei An, Yue-yi Deng, Jian Feng, Zhi-man Yu, Hai-yin wang. Treatment of IgA nephropathy based on syndrome differentiation: A report of 20 cases. Journal of Chinese Integrative Medicine, 2004, 2(1): 35-35.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] Jin-rong Fu. Establishment of multivariate diagnosis and treatment system of modern gynecology of traditional Chinese medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 22-24
[2] Hao Li, Ming-jiang Yao, Wen-ming Zhao, Jie Guan, Lin-lin Cai, Ling Cui. A randomized, controlled, double-blind trial of Huannao Yicong capsule in senile patients with mild cognitive impairment. Journal of Chinese Integrative Medicine, 2008, 6(1): 25-31
[3] Zhi-chun Jin. Problems in establishing clinical guideline for integrated traditional Chinese and Western medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 5-8
[4] SUN Ming-yu, ZUO Jian, DUAN Ji-feng, HAN Jun, FAN Shi-ming, ZHANG Wei, ZHU Li-fang, YAO Ming-hui. Antitumor activities of kushen flavonoids in vivo and in vitro. Journal of Chinese Integrative Medicine, 2008, 6(1): 51-59
[5] Min Cheng, Qiong Feng, Shu-wen Qian, Hui Gao, Cui-qing Zhu. Preliminary assay of p-amyloid binding elements in heart-beneficial recipe. Journal of Chinese Integrative Medicine, 2008, 6(1): 68-72
[6] Ning-qun Wang, Liang-duo Jiang, Zong-xing Li. Research progress in asthma-related quality of life. Journal of Chinese Integrative Medicine, 2008, 6(1): 93-97
[7] Jing-yuan Mao, Chang-xiao Liu, Heng-he Wang, Guang-li Wei , Zhen-peng Zhang, Jie Xing, Wang Xian liang , Ying-fei Bi . Effects of Shenmai Injection on serum concentration and pharmacokinetics of digoxin in dogs with heart failure. Journal of Chinese Integrative Medicine, 2010, 8(11): 1070-1074
[8] Zhi-mei Wang, Bin Zhang. A study on translation of ellipses in Huangdi Neijing from perspective of hermeneutic theory. Journal of Chinese Integrative Medicine, 2010, 8(11): 1097-1100
[9] Gui Yu, Jie Wang. Thinking on building the network cardiovasology of Chinese medicine. Journal of Chinese Integrative Medicine, 2012, 10(11): 1206-1210
[10] Pedro Saganha João, Doenitz Christoph, Greten Tobias, Efferth Thomas, J. Greten Henry. Qigong therapy for physiotherapists suffering from burnout: a preliminary study. Journal of Chinese Integrative Medicine, 2012, 10(11): 1233-1239
[an error occurred while processing this directive]